Reduced Nerve Injury-Induced Neuropathic Pain in Kinin B₁ Receptor Knock-Out Mice

Juliano Ferreira, 1 Alessandra Beirith, 1 Marcelo A. S. Mori, 2 Ronaldo C. Araújo, 3 Michael Bader, 4 João B. Pesquero, 2 and João B. Calixto 1

1 Department of Pharmacology, Centre of Biological Sciences, Universidade Federal de Santa Catarina, 88015-420 Florianópolis, Brazil, 2 Department of Biophysics, Escola Paulista de Medicina, 04023-062 São Paulo, Brazil, 3 Universidade de Mogi das Cruzes, 08780-91 Mogi das Cruzes, Brazil, and 4 Max-Delbrück-Center for Molecular Medicine, D-13125 Berlin-Buch, Germany

Injury to peripheral nerves often results in a persistent neuropathic pain condition that is characterized by spontaneous pain, allodynia, and hyperalgesia. Nerve injury is accompanied by a local inflammatory reaction in which nerve-associated and immune cells release several pronociceptive mediators. Kinin B₁ receptors are rarely expressed in nontraumatized tissues, but they can be expressed after tissue injury. Because B₁ receptors mediate chronic inflammatory painful processes, we studied their participation in neuropathic pain using receptor gene-deleted mice. In the absence of neuropathy, we found no difference in the paw-withdrawal responses to thermal or mechanical stimulation between B₁ receptor knock-out mice and 129/J wild-type mice. Partial ligation of the sciatic nerve in the wild-type mouse produced a profound and long-lasting decrease in thermal and mechanical thresholds in the paw ipsilateral to nerve lesion. Threshold changed neither in the sham-operated animals nor in the paw contralateral to lesion. Ablation of the gene for the B₁ receptor in the mouse produced a profound and long-lasting decrease in thermal and mechanical thresholds in the paw ipsilateral to nerve lesion. Ablation of the gene for the B₁ receptor in the mouse resulted in a significant reduction in early stages of mechanical allodynia and thermal hyperalgesia. Furthermore, systemic treatment using receptor gene-deleted mice. In the absence of neuropathy, we found no difference in the paw-withdrawal responses to thermal or mechanical stimulation between B₁ receptor knock-out mice and 129/J wild-type mice. Partial ligation of the sciatic nerve in the wild-type mouse produced a profound and long-lasting decrease in thermal and mechanical thresholds in the paw ipsilateral to nerve lesion. Threshold changed neither in the sham-operated animals nor in the paw contralateral to lesion. Ablation of the gene for the B₁ receptor in the mouse resulted in a significant reduction in early stages of mechanical allodynia and thermal hyperalgesia. Furthermore, systemic treatment with the B₁ selective receptor antagonist des-Arg⁹-[Leu⁸]-bradykinin reduced the established mechanical allodynia observed 7–28 d after nerve lesion in wild-type mice. Partial sciatic nerve ligation induced an upregulation in B₁ receptor mRNA in ipsilateral paw, sciatic nerve, and spinal cord of wild-type mice. Together, kinin B₁ receptor activation seems to be essential to neuropathic pain development, suggesting that an oral-selective B₁ receptor antagonist might have therapeutic potential in the management of chronic pain.

Key words: neuropathic pain; allodynia; hyperalgesia; B₁ receptor; kinin; bradykinin

Introduction

Injury to a peripheral nerve in humans often results in a persistent neuropathic pain condition that is characterized by spontaneous pain, allodynia, and hyperalgesia. Nerve injury is accompanied by a local inflammatory reaction in which nerve-associated and immune cells release several pronociceptive mediators. Kinin B₁ receptors are rarely expressed in nontraumatized tissues, but they can be expressed under certain conditions, such as neuroplasticity, that have been described at various levels of the nervous system (Besson, 1999). Thus, the available analgesic drugs often have limited therapeutic value in the management of chronic pain and they may, in fact, represent a risk to the patient because of their common side effects (Woolf and Mannion, 1999). Therefore, the development of safe and efficacious drugs to treat chronic pain is an urgent priority.

Nerve injury is accompanied by a local inflammatory reaction in which nerve-associated and immune cells release several pronociceptive mediators such as cytokines, eicosanoids, and kinins (Tracey and Walker, 1995; Bennett, 1999). Of note, increased serum bradykinin levels have been found in patients with neuropathic pain (Blair et al., 1998).

Kinins are peptides formed in plasma and peripheral tissues in response to the activation of a class of enzymes, denoted “kalikreins,” on kinogen substrates. Kinins are involved in a wide range of physiological mechanisms, including control of blood pressure, smooth-muscle contraction or relaxation, vascular permeability, and pain transmission. Furthermore, kinins are implicated in pathological states such as arthritis, pancreatitis, and asthma (for review, see Calixto et al., 2000, 2004). The actions of kinins are mediated through the stimulation of two subtypes of G-protein-coupled receptors, denoted B₁ and B₂. The kinin B₁ receptors exhibit higher affinity for the carboxypeptidase metabolites of kinins, des-Arg⁹-bradykinin and des-Arg⁸;kallidin. Usually, the B₁ receptors are hardly expressed in nontraumatized tissues, but they can be expressed under certain conditions, such as those after tissue injury and infection (for review, see Marceau et al., 1998). In contrast, the B₂ receptors for which bradykinin and kallidin exhibit great affinity are usually constitutively ex-
pressed and widely distributed throughout central and peripheral tissues (for review, see Calixto et al., 2000, 2004).

Once formed in the periphery, kinins activate Aδ and C fibers in sensory nerves producing pain, hyperalgesia, or allodynia in both humans and experimental animals. In addition, kinins may cause the release of other mediators such as neurokinins, calcitonin gene-related peptide, nitric oxide, and arachidonic acid metabolites, which also account for primarily their proinflammatory and nociceptive properties (for review, see Calixto et al., 2000, 2004) (Dray and Perkins, 1997).

Recently, the use of both B1 and B2 knock-out mice has led to a better understanding of the role played by kinins in physiological and pathological processes (Borkowski et al., 1995; Pesquero et al., 2000). For example, the deletion of the B1 receptor gene significantly decreases acute and chronic inflammatory nociception (Pesquero et al., 2000; Ferreira et al., 2001, 2002). In the present study, we examine the contribution of the kinin B1 receptor to the chronic nociception produced by peripheral nerve injury using knock-out mice, selective drugs, and the measurement of mRNA levels.

Materials and Methods

Animals. Experiments were conducted using male and female wild-type 129/J mice and kinin B1 receptor knock-out mice (20–30 g; 129/J background) kept at controlled room temperature (22 ± 2°C) under a 12 h light/dark cycle (lights on at 6:00 A.M.) and 60–90% humidity. The animals were obtained from the Department of Biophysics at the Federal University of São Paulo (Brazil). Deletion of the entire coding sequence for the kinin B1 receptor was achieved as described previously (Pesquero et al., 2000). The experiments were performed in accordance with current guidelines for the care of laboratory animals and ethical guidelines for the investigation of pain in conscious animals (Zimmermann, 1983).

The number of animals and intensity of noxious stimuli used were the minimum necessary to demonstrate the consistent effects of drug treatments or genetic manipulation.

Partial sciatic nerve ligation. For the induction of chronic neuropathy, male and female mice were anesthetized by intraperitoneal injection of 7% chloral hydrate (0.6 ml/kg; Vetec, Rio de Janeiro, Brazil). A partial ligation of the right sciatic nerve was made by tying one-third to one-half of the dorsal portion of the sciatic nerve, using a similar procedure to that described for rats by Seltzer et al. (1990) and for mice by Malmberg and Basbaum (1998). In sham-operated mice, the nerve was exposed without ligation.

Measurement of thermal hyperalgesia. Thermal hyperalgesia was measured using the paw-withdrawal latency according to the method described by Hargreaves et al. (1988), with minor modifications. After challenge, hyperalgesia was measured at several time points after nerve injury (1–42 d), as described below. Thermal baseline measures were obtained from nonoperated animals 1 d before nerve injury. Mice were placed in clear plastic chambers (9 × 9 × 11 cm) on an elevated surface and allowed to acclimatize to their environment for 1.5 h before testing. The heat stimulus was directed to the plantar surface of each hindpaw in the area immediately proximal to the toes. The infrared intensity was adjusted to obtain basal paw-withdrawal latencies of ~11 s. An automatic 20 s cutoff was used to prevent tissue damage.

Measurement of mechanical allodynia. Mechanical nociceptive thresholds in mice were measured as the withdrawal response frequency to application of von Frey hairs (Stoelting, Chicago, IL). Six hairs with forces of 0.07, 0.16, 0.6, 1, 2, and 4 g were applied 10 times each to the plantar surface of each hindpaw following an alternating sequence and in ascending order of force. The monofilament was applied at intervals of 2 s to slightly different loci on the plantar surface of both hindpaws. A positive withdrawal response was considered valid only when the hindpaw was completely removed from the platform. The frequency of positive responses was calculated after 10 applications of the filament. The frequency of response was measured before and 1–42 d after nerve injury. Mechanical baseline measures were obtained from nonoperated animals 1 d before nerve injury. Mice were placed individually in clear Plexiglas boxes (9 × 7 × 11 cm) on elevated wire mesh platforms to allow access to the ventral surface of the hindpaws. Animals were acclimatized to the testing chambers, and the static mechanical withdrawal threshold was determined before and after nerve injury. The involvement of the B1 receptor in mechanical allodynia was tested by using the selective antagonists of the B1 receptor des-Arg(9)-Leu(1)-bradykinin (150 nmol/kg, s.c.; Sigma, St. Louis, MO) (Ferreira et al., 2001).

Quantitative real-time PCR. The expression of B1 receptor mRNA was measured using a quantitative real-time PCR according to the method described previously (Argañaraz et al., 2004). Several days after nerve lesion, mice (n = 3–6 for each group) were killed, and the plantar skin of the right hindpaw, right sciatic nerve, dorsal portion of spinal cord, and whole cerebral cortex were isolated, dissected, and frozen in liquid nitrogen and stored at ~80°C. Thawed tissue was homogenized in 0.3–1 ml of TRIzol reagent (Invitrogen, Gaithersburg, MD), and total RNA was isolated according to the instructions of the manufacturer. Before cDNA synthesis, RNA samples were pretreated with DNase I (Invitrogen) to avoid genomic DNA contamination. Reverse transcription was performed using 2 μg of total pure RNA, 50 ng of random hexamer primers, and 200 U of Maloney murine leukemia virus reverse transcriptase (Invitrogen), as described by the manufacturers. Samples were submitted to a 20 μl reaction using TaqMan Amplification system with an ABI PRISM 7000 Sequence Detection system (Applied Biosystems, Foster City, CA). Multiplex reactions were performed with 600 ng of cDNA for kinin B1 receptor and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) amplification. Oligonucleotide primers and fluorescent probes for the TaqMan real-time PCR were designed for kinin B1 receptor using Assays-by-Design service (Applied Biosystems) to meet all TaqMan design guidelines. The probes were synthesized with the reporter dye 6-carboxyfluorescein (6-FAM) covalently linked at the 5′-end, and the quencher dye 6-carboxy-tetramethyl-rhodamine was linked to the 3′-end of the probe. For GAPDH amplification, commercial TaqMan reverse control reagents (Applied Biosystems) were used. Differently from kinin B1 receptor probe, the GAPDH probe was VIC-labeled, allowing us to use it for multiplex detection. Each reaction was performed with 10 μl of Master Mix (Applied Biosystems), 1 μl of a mix containing two primers (18 μM each) and a probe (5 μM) specific to mRNA of kinin B1 receptor (probe B1:5′-CACAGGACCACACGAC-3′, forward primer: 5′-CCATACAAATAACCCCGATGCAA-3′, reverse primer: 5′-CTTTGTTAAGGCGTGATCGTCTA-3′), and 1 μl of each GAPDH primer and the VIC-labeled probe (10 μM each). The cycle conditions were as follows: 50°C for 2 min and then 95°C for 10 min, followed by 50 cycles of 95°C for 15 s (melting step), and 60°C for 1 min (anneal/extend step). Both FAM and VIC correspondent fluorences were acquired at the end of each cycle.

The PCR cycle was considered a genefocused threshold is crossed by the amplification curve, was considered our first parameter to analyze mRNA expression and named Ct. ΔCt values were calculated by subtracting GAPDH Ct from kinin B1 receptor Ct to obtain the 2−ΔΔCt parameter, which represents relative B1 receptor/GAPDH expression.

Measurement of overt nociception. The procedure used was similar to that described previously (Ferreira et al., 2004). Twenty microliters of des-Arg(9)-bradykinin solution (10 nmol/paw; Sigma) were injected intraplantarly under the surface of the right hindpaw 7 d after sham surgery or partial sciatic nerve lesion in wild-type mice. Separate groups of animals received an intraplantar injection of vehicle (PBS). Animals were placed individually in chambers (transparent glass cylinders of 20 cm diameter) and were adapted for 20 min before algogen or vehicle injection. After challenge, mice were observed individually for 10 min. The amount of time spent licking the injected paw was measured with a chronometer and was considered as indicative of overt nociception.

Skin temperature measurement. Apart from nociceptive hypersensitivity, sciatic nerve lesions may cause abnormal cutaneous temperature regulation. Thus, the skin temperature of the ipsilateral and contralateral paw was measured 7 d after surgery using a surface radiation thermometer (Pro Check, Taipei, Taiwan) as described previously (Ferreira et al., 2004).

Data analysis. The results are presented as means ± SEM of four to six animals. The statistical significance of differences between groups was
analyzed by means of Student’s t test or ANOVA followed by Student–Newman–Keuls test when appropriate. p values <0.05 were considered indicative of significance.

Results

Partial ligation of the sciatic nerve in the wild-type mouse produced a profound and prolonged decrease in thermal and mechanical nociceptive thresholds observed in the paw ipsilateral to the nerve lesion (Figs. 1, 2). Neither threshold changed in the sham-operated animals or in the paw contralateral to the lesion (Figs. 1, 2). We found a significant reduction in the paw-withdrawal latency to the heat stimulus as early as 1 d after nerve injury that was stable until 21 d compared with sham-operated wild-type animals (Fig. 1 A). At 28 d after the nerve injury, the paw-withdrawal latencies to thermal stimulation returned to baseline values (Fig. 1 A).

In the absence of neuropathy, we found no difference in the paw-withdrawal responses to thermal stimulation between B₁ receptor knock-out mice and wild-type mice (10.3 ± 0.7 and 10.5 ± 0.6 s, respectively). Ablation of the gene for the B₁ receptor caused a significant reduction in thermal hyperalgesia produced by nerve injury (Fig. 1 A). This anti-hyperalgesic response was observed from 1 to 21 d after lesion.

Before nerve injury, wild-type mice showed an increase in the frequency of responses to mechanical stimulation with von Frey hairs of higher forces (1–4 g) but little change in the responses to weaker von Frey hairs (0.07–0.6 g) (Fig. 2 A). Moreover, B₁ receptor knock-out mice displayed a similar pattern of response to high and weak mechanical stimulation (Fig. 2 A). Thus, von Frey hairs from 0.07 to 0.6 g were considered innocuous stimuli for both wild-type and B₁ receptor knock-out mice.

Mechanical allodynia produced by nerve injury was characterized by a pronounced and long-lasting increase in response frequency to innocuous von Frey hairs stimulation in the paw ipsilateral to the lesion (Fig. 2 B). In contrast to thermal hyperal-
gesia, mechanical allodynia developed at day 1, reached a maximum at day 7 after nerve ligation, and remained increased for 42 d (Fig. 3A). B1 receptor gene deletion completely reversed mechanical allodynia from 1 to 28 d after nerve injury (Fig. 3A). However, this anti-allodynic effect became only partial 35 d after lesion and disappeared at day 42 (Fig. 3B). Moreover, we were not able to detect mechanical allodynia in the contralateral paw (data not shown).

To further confirm the participation of the B1 receptor in neuropathic pain, a separate group of wild-type mice was treated with the selective B1 receptor antagonist des-Arg9-[Leu8]-bradykinin (150 nmol/kg, s.c.). Des-Arg9-[Leu8]-bradykinin administration to wild-type mice 7 d after partial sciatic nerve ligation, when the maximal pain hypersensitivity is already installed, also greatly reduced the mechanical allodynia (Fig. 4). The antinociceptive effect of des-Arg9-[Leu8]-bradykinin was short-lasting, maximal 1 h after treatment (inhibition of 69.6 ± 5.9%). In agreement with that after gene deletion, this dose of antagonist did not alter the frequency responses of mechanical stimulation of sham-operated animals (50 ± 5.7 and 45 ± 5.0% of frequency responses against 2.0 g of stimulation when assessed 7 d after injury). As occurred for the gene lacking, the treatment with des-Arg9-[Leu8]-bradykinin was also capable of reducing mechanical allodynia when the antagonist was administered 14 and 28 d, but not 42 d, after nerve injury (Fig. 4B).

Next, the expression of B1 receptor mRNA was quantified by real-time reverse transcription (RT)-PCR in tissues of mice after sciatic nerve lesion or sham operation. Basal expression of B1 receptor mRNA was detected in plantar hindpaw skin, sciatic nerve, spinal cord, and cerebral cortex of wild-type mice (Fig. 5). However, 7 d after nerve lesion, we observed an increased of B1 expression in ipsilateral paw skin, right sciatic nerve, and spinal cord obtained from operated mice (Fig. 5). No expression of B1 receptor mRNA could be detected in B1 receptor gene-deficient mice (results not shown). Moreover, the increase of expression of B1 receptor mRNA was also detected in paw skin of injured wild-type mice 14, 28, and 42 d after nerve injury (441 ± 216, 241 ±
127, 849 ± 103% of increase over sham-operated animals, respectively). These results suggested that the increase in mRNA appears to mainly relate with the development and the maintenance of early stages of neuropathic pain but not with the maintenance of its late stage. In fact, intraplantar injection of the selective B1 receptor agonist des-Arg9-bradykinin produced overt nociception in ligated but not in, when assessed, sham-operated wild-type mice 7 d after surgery (Fig. 6A).

In addition to nociceptive hypersensitivity, other symptoms similar to clinical features of human neuropathies may occur after partial sciatic nerve ligation in mice, including abnormal cutaneous temperature regulation. Accordingly, we observed a significant increase in the skin surface temperature of the ipsilateral paw 7 d after nerve injury in wild-type mice (Fig. 6B). Notably, the B1 receptor gene deletion abolished this cutaneous heating (Fig. 6B). However, we were not able to detect significant modifications in skin temperature from 14 to 42 d after nerve injury either in operated or in sham-operated animals (results not shown).

Discussion

Painful neuropathies may result from nerve injury as well as the effects of drugs, diseases, toxins, and metabolic disorders (Woolf and Mannion, 1999). Because of the as yet poor understanding of the mechanisms underlying these syndromes, therapy does not provide satisfactory pain relief for many patients. Consequently, these patients suffer from chronic intractable pain (Seltzer, 1995).

Several studies have demonstrated the participation of kinins and their receptors in neuropathic pain induction. Increased levels of B1 and B2 receptor mRNA or protein have been found in dorsal root ganglia (DRGs) after sciatic nerve constriction in rats and mice (Petersen et al., 1998; Eckert et al., 1999; Levy and Zochodne, 2000; Yamaguchi-Sase et al., 2003; Rashid et al., 2004). Of note, the systemic administration of B1 or B2 receptor antagonists has been found to reduce thermal hyperalgesia and mechanical allodynia produced by sciatic nerve constriction in rats (Levy and Zochodne, 2000; Yamaguchi-Sase et al., 2003; Gougat et al., 2004). Plasma seems to be the main source of endogenous kinins after nerve injury, and there is recent evidence demonstrated that neuropathic pain is reduced in mutant plasma kininogen-deficient B/N-Katholiek rats when compared with normal B/N-Kitasato rats (Yamaguchi-Sase et al., 2003).

The present work extended these previous observations by demonstrating that gene deletion or pharmacological inhibition of the B1 receptor in mice practically abolished the nociceptive hypersensitivity produced by nerve injury. This effect appeared as early as 1 d after lesion, and it was found significant until 28 d after the surgery, suggesting that the B1 receptor is critically involved in both the development and the early maintenance of neuropathic pain symptoms. In contrast, thermal hyperalgesia was not observed, and mechanical allodynia was reduced only in the later stages of nerve injury (35–42 d after surgery), despite the detection of increased levels of B1 receptor mRNA. Interestingly, at this time, the mechanical allodynia was reinstalled in B1 receptor knock-out mice, and the B1 receptor antagonist was not capable of reducing allodynia. Because regeneration occurs after constrictive injury to the sciatic nerve (Myers et al., 1996), it is quite possible that under this circumstance, B1 receptor activity is...
not relevant to the production of neuropathic pain and probably other mediators substitute for the nociceptive action of kinins.

Pain is produced by the stimulation of small-diameter primary afferent fibers that innervate regions of the head and body and arise from cell bodies in the trigeminal ganglion and DRG, respectively (Julius and Basbaum, 2001). B1 receptor mRNA and protein are constitutively expressed in mouse, rat, and monkey DRG (Seabrook et al., 1997; Levy and Zochodne, 2000; Ma et al., 2000; Wotherspoon and Winter, 2000; Shughrue et al., 2003; Yamaguchi-Sase et al., 2003; Rashid et al., 2004). B1 receptors are predominantly expressed by small-diameter DRG neurons colocalized with isoleucine B4 and calcitonin gene-related peptide that are contained in C and Aδ fibers (Ma, 2001). Moreover, the B1 receptor is expressed in both peripheral and spinal terminals of primary afferent fibers (Wotherspoon and Winter, 2000; Ma and Heavens, 2001; Shughrue et al., 2003). B1 receptors are newly expressed 7 d after partial sciatic nerve injury in mice mainly in non-neuronal satellite cells and in large myelinated DRG neurons (Rashid et al., 2004). Because there is evidence that large A fibers mediate the mechanical allodynia in rats with partial sciatic nerve lesion (Shir and Seltzer, 1990) and B1 receptor knock-out mice have reduced allodynia, it seems that this novel expression of B1 receptors is potentially related to the production of the persistent mechanical allodynia observed in the early stages of neuropathy.

In the present study, we have shown that B1 receptor mRNA was normally expressed in some tissues important for the detection, transmission, and modulation of pain, including plantar paw skin, sciatic nerve, spinal cord, and cerebral cortex. Moreover, the involvement of B1 receptors in neuropathy was further confirmed by the upregulation of B1 receptor mRNA several days after sciatic nerve injury. It has been well demonstrated that several stimuli are able to upregulate B1 receptor, including proinflammatory cytokines, mitogen-activated protein kinases (MAPK), and nuclear factor κB (NFκB) (for review, see Calixto et al., 2000, 2004). We can suggest that similar mechanisms might be involved in B1 receptor upregulation in the present study, because proinflammatory cytokines are produced, and MAPK and NFκB are activated after sciatic nerve injury (Ma and Bisby, 1998; Okamoto et al., 2001; Ma and Quirion, 2002). We also observed an increase in levels of B1 receptor mRNA in samples of ipsilateral paw skin and sciatic nerve 7 d after injury, a finding that could suggest a role for B1 receptors in the abnormal perception of noxious and innocuous stimuli seen in early stages of neuropathy. This upregulation seems to be functional, because the intraplantar injection of the selective B1 receptor agonist des-Arg9-bradykinin produced overt nociception in nerve-injured, but not in sham-operated, wild-type mice. These results reinforce the recent data obtained by Rashid et al. (2004), showing that intraplantar administration of des-Arg10-kallidin was able to induce both nociceptive reflex and activation of ERK (extracellular signal-regulated kinase) in DRG neurons in ligated, but not sham-operated, mice.

B1 receptors are also found in the CNS, which contains all of the components of the kallikrein-kinin system and is also involved in nociceptive processing (Couture and Lindsay, 2000; Ferreira et al., 2002). B1 receptors have been identified in the superficial layers of the dorsal horn confined mainly to the terminals of primary sensory nerve fibers (Couture and Lindsay, 2000; Wotherspoon and Winter, 2000). Using an in vitro spinal cord preparation, Pesquero et al. (2000) demonstrated that B1 receptor stimulation increases the C-fiber component, but not the Aβ-fiber component, of the ventral root potential produced by electrical excitation of the dorsal root of naive mice. This indicates that the B1 receptor functions specifically in nociceptive synaptic pathways and appears to be involved in some forms of central sensitization. In fact, intrathecal injection of B1 receptor antagonists reduces the inflammatory phase of formalin-induced pain and chronic inflammatory pain caused by Complete Freund’s Adjuvant in mice and rats (Ferreira et al., 2002; Fox et al., 2003). Moreover, the use-dependent facilitation of spinal cord neuron firing (wind-up) was significantly reduced (~50%) in B1 receptor knock-out mice when compared with the wild-type littermates (Pesquero et al., 2000). We have shown that B1 receptor mRNA is upregulated in dorsal spinal cord after partial sciatic nerve lesion, further suggesting a role for spinal B1 receptors in neuropathy. Because the development of spinal sensitization is an important consequence of nerve injury (Sah et al., 2003), these data indicate that the nociceptive impairment observed in B1 receptor knock-out mice might be attributed to, at least in part, a deficit in the pathological plasticity of the spinal neurons.

Subsets of dorsal horn neurons that project axons and transmit pain messages to higher brain structures are involved in the somatic, affective, and autonomic responses to pain (Hunt and Mantyh, 2001). In this respect, we have shown that B1 receptor mRNA is constitutively expressed in the cerebral cortex of mice. This result is in line with literature showing basal B1 receptor expression in rat somatosensory cortex (Ongali et al., 2003; Shughrue et al., 2003). However, the function of cortical B1 receptors still remains obscure.

Besides thermal and mechanical hypersensitivity, animals subjected to sciatic nerve injury exhibit other signs similar to clinical features of human painful neuropathies, including abnormal sympathetic activity, abnormal growth of hair, and cutaneous temperature regulation (Wakisaka et al., 1994). Similar to our observations in mice, the ipsilateral plantar surface in rats was warmer than that of the contralateral paw during the first week after loose ligation of sciatic nerve, thereafter becoming cooler (Wakisaka et al., 1991, 1994). It has been reported that early heating of the paw surface is dependent on sympathetic vasconstriction (Wakisaka et al., 1994). Furthermore, partial nerve injury-induced pain is mediated by sympathetic activity (Shir and Seltzer, 1991; Malmberg and Basbaum, 1998). Interestingly, functional B1 receptors are expressed in sympathetic neurons, because their activation by agonists is able to depolarize superior cervical ganglia neurons in vitro (Seabrook et al., 1995, 1997). In addition, postganglionic sympathetic terminals are involved in B1 receptor agonist-induced hyperalgesia (Khasar et al., 1995). However, the participation of sympathetic fibers in nociception mediated by B1 receptors activation during neuropathy still needs to be determined.

Besides being caused by nerve injury, painful neuropathy may also develop in diabetes (Woolf and Mannion, 1999; Sah et al., 2003). It has been reported recently that thermal hyperalgesia in diabetic mice was blocked by the systemic treatment with selective B1 receptor antagonists (Gabra and Sirois, 2002, 2003a,b). Moreover, intrathecal administration of a B1 receptor agonist produces thermal hyperalgesia in hyperglycemic rats (Couture et al., 2001). Thus, the activation of B1 receptors is a critical step in the production of neuropathic pain, and B1 receptor blockade is able to not only prevent the development of nociception but also reduce an established painful condition. Of interest are the results showing that oral treatment with the newly synthesized nonpeptide B1 receptor antagonist SSR240612 [(2R)-2-(((3R)-3-(1,3-benzodioxol-5-yl)-3-([6-methoxy-2-naphthyl)sulfonyl]amino) propanoyl)amino]-3-(4-[[2R,6S]-2,6-dimethylpiperidinyl]methyl]
phenyl)-N-isopropyl-N-methylpropanamide hydrochloride] was able to reduce the thermal hyperalgesia produced by sciatic nerve injury in rats (Gougat et al., 2004). These findings support the notion that the development of oral-selective B1 receptor antagonists might be expected to have clinical therapeutic potential in the management of neuropathic pain.

References


